Q32 Bio Q3 2026 net loss widens 20% to $8.9 million year over year

Bitget2026/11/04 12:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Q32 Bio’s third-quarter 2026 net loss widened 20% year over year to $8.9 million.
Research and development expenses rose 42% to $5.1 million; general and administrative expenses climbed 38% to $5.5 million.
Cash and cash equivalents totaled $289.6 million at September 30, expected to fund operations through planned Phase 3 topline results.
A registration-directed bempikibart program for severe or very severe alopecia areata is expected to begin in first-half 2027, subject to regulatory discussions.
Bempikibart responses were maintained or deepened during SIGNAL-AA’s 16-week off-drug follow-up, supporting potential for less frequent maintenance dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-446183), on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Q32 Bio Q3 2026 net loss widens 20% to $8.9 million year over year

You may also like

Crypto prices